| Aug 13 |
Mind Medicine (MindMed) Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 13 |
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Mind Medicine GAAP EPS of -$0.26 beats by $0.07
|
| Aug 13 |
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
|
| Aug 13 |
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
| Aug 12 |
Medical journal retracts three articles related to MDMA for PTSD
|
| Aug 12 |
Mind Medicine Q2 2024 Earnings Preview
|
| Aug 9 |
Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA
|
| Aug 9 |
Mind Medicine prices $75M securities offering
|
| Aug 9 |
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
|
